Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC

NCT03769103 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer Non-small Cell Stage IV
Brain Metastases

Interventions

DRUG: Osimertinib
RADIATION: Stereotactic radiotherapy

Sponsor

British Columbia Cancer Agency

Collaborators

[object Object]
[object Object]
[object Object]